Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer

Kristin A. Skinner, Gary Dunnington, Howard Silberman, Barbara Florentine, Darcy Spicer, Silvia C. Formenti

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: Fifteen percent of breast cancer patients present with large tumors involving skin or chest wall. Often, surgery with primary wound closure is impossible. We used neoadjuvant chemoradiation in locally advanced breast cancer patients, in hopes of increasing resectability. METHODS: Eligible patients had locally advanced breast cancer deemed unresectable with primary wound closure. Patients received 8 weeks of infusional 5-fluorouracil (5-FU) 200 mg/m2 per day and radiation therapy to 50 Gy. Patients rendered resectable underwent modified radical mastectomy (MRM) followed up by chemotherapy. RESULTS: Of 30 evaluable patients, 73% had an objective clinical response. All were able to undergo MRM with primary wound closure; 63% had residual disease, 20% had minimal microscopic disease, and 17% had complete pathologic response. Treatment-related toxicity was minimal. Surgical morbidity was not increased. CONCLUSIONS: Infusional 5-FU with concomitant radiotherapy is well tolerated and effective at producing shrinkage in the majority of patients, converting inoperable breast cancer to easily resectable disease.

Original languageEnglish (US)
Pages (from-to)705-708
Number of pages4
JournalAmerican Journal of Surgery
Volume174
Issue number6
DOIs
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Fluorouracil
Radiotherapy
Breast Neoplasms
Modified Radical Mastectomy
Wounds and Injuries
Thoracic Wall
Morbidity
Drug Therapy
Skin
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer. / Skinner, Kristin A.; Dunnington, Gary; Silberman, Howard; Florentine, Barbara; Spicer, Darcy; Formenti, Silvia C.

In: American Journal of Surgery, Vol. 174, No. 6, 12.1997, p. 705-708.

Research output: Contribution to journalArticle

Skinner, Kristin A. ; Dunnington, Gary ; Silberman, Howard ; Florentine, Barbara ; Spicer, Darcy ; Formenti, Silvia C. / Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer. In: American Journal of Surgery. 1997 ; Vol. 174, No. 6. pp. 705-708.
@article{1b208250913641ca9ed7dc4bb79753c9,
title = "Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer",
abstract = "BACKGROUND: Fifteen percent of breast cancer patients present with large tumors involving skin or chest wall. Often, surgery with primary wound closure is impossible. We used neoadjuvant chemoradiation in locally advanced breast cancer patients, in hopes of increasing resectability. METHODS: Eligible patients had locally advanced breast cancer deemed unresectable with primary wound closure. Patients received 8 weeks of infusional 5-fluorouracil (5-FU) 200 mg/m2 per day and radiation therapy to 50 Gy. Patients rendered resectable underwent modified radical mastectomy (MRM) followed up by chemotherapy. RESULTS: Of 30 evaluable patients, 73{\%} had an objective clinical response. All were able to undergo MRM with primary wound closure; 63{\%} had residual disease, 20{\%} had minimal microscopic disease, and 17{\%} had complete pathologic response. Treatment-related toxicity was minimal. Surgical morbidity was not increased. CONCLUSIONS: Infusional 5-FU with concomitant radiotherapy is well tolerated and effective at producing shrinkage in the majority of patients, converting inoperable breast cancer to easily resectable disease.",
author = "Skinner, {Kristin A.} and Gary Dunnington and Howard Silberman and Barbara Florentine and Darcy Spicer and Formenti, {Silvia C.}",
year = "1997",
month = "12",
doi = "10.1016/S0002-9610(97)00198-0",
language = "English (US)",
volume = "174",
pages = "705--708",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer

AU - Skinner, Kristin A.

AU - Dunnington, Gary

AU - Silberman, Howard

AU - Florentine, Barbara

AU - Spicer, Darcy

AU - Formenti, Silvia C.

PY - 1997/12

Y1 - 1997/12

N2 - BACKGROUND: Fifteen percent of breast cancer patients present with large tumors involving skin or chest wall. Often, surgery with primary wound closure is impossible. We used neoadjuvant chemoradiation in locally advanced breast cancer patients, in hopes of increasing resectability. METHODS: Eligible patients had locally advanced breast cancer deemed unresectable with primary wound closure. Patients received 8 weeks of infusional 5-fluorouracil (5-FU) 200 mg/m2 per day and radiation therapy to 50 Gy. Patients rendered resectable underwent modified radical mastectomy (MRM) followed up by chemotherapy. RESULTS: Of 30 evaluable patients, 73% had an objective clinical response. All were able to undergo MRM with primary wound closure; 63% had residual disease, 20% had minimal microscopic disease, and 17% had complete pathologic response. Treatment-related toxicity was minimal. Surgical morbidity was not increased. CONCLUSIONS: Infusional 5-FU with concomitant radiotherapy is well tolerated and effective at producing shrinkage in the majority of patients, converting inoperable breast cancer to easily resectable disease.

AB - BACKGROUND: Fifteen percent of breast cancer patients present with large tumors involving skin or chest wall. Often, surgery with primary wound closure is impossible. We used neoadjuvant chemoradiation in locally advanced breast cancer patients, in hopes of increasing resectability. METHODS: Eligible patients had locally advanced breast cancer deemed unresectable with primary wound closure. Patients received 8 weeks of infusional 5-fluorouracil (5-FU) 200 mg/m2 per day and radiation therapy to 50 Gy. Patients rendered resectable underwent modified radical mastectomy (MRM) followed up by chemotherapy. RESULTS: Of 30 evaluable patients, 73% had an objective clinical response. All were able to undergo MRM with primary wound closure; 63% had residual disease, 20% had minimal microscopic disease, and 17% had complete pathologic response. Treatment-related toxicity was minimal. Surgical morbidity was not increased. CONCLUSIONS: Infusional 5-FU with concomitant radiotherapy is well tolerated and effective at producing shrinkage in the majority of patients, converting inoperable breast cancer to easily resectable disease.

UR - http://www.scopus.com/inward/record.url?scp=0031472318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031472318&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(97)00198-0

DO - 10.1016/S0002-9610(97)00198-0

M3 - Article

C2 - 9409601

AN - SCOPUS:0031472318

VL - 174

SP - 705

EP - 708

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 6

ER -